The document provides an overview of the SARS-CoV-2 virus, noting its emergence in late 2019 in Wuhan, China and its global spread. It discusses the virus structure, life cycle, and potential treatment strategies targeting both the virus and host response. Additionally, it outlines drug discovery services and development related to SARS-CoV-2, including vaccines and diagnostics.

1. SARS-CoV-2 Introduction

2. End of 2019 - Wuhan, China
Now – Spread in over 200 countries (WHO)
January 30, 2020 - PHEIC February 11, 2020 - Named SARS-CoV-2
January, 2020 - Named 2019-nCoV
SARS-CoV-2 Outbreak Process

3. Mammals Birds and
Mammals
The SARS-CoV-2 virus that causes COVID-19 belongs to the
Coronaviridae family.
SARS-CoV-2
Coronaviruses Family

4. Spike Glycoprotein (S)
Get the virus into the cell
Hemagglutinin-esterase (HE)
May facilitate the virus to initially adsorb
the cell membrane
RNA and N Protein
N protein is related to the formation of
nucleocapsid in RNA genome
E-Protein
The smallest and most mysterious
Envelope
SARS-CoV-2 Structure
M-Protein
Virus germination and envelope formation

5. ACE2
1 Fusion
2 Replicate Assembly3
Release4
SARS-CoV-2 Life Cycle

6. Screen the existing broad-spectrum
antiviral drugs.
Use existing molecular libraries and
databases to screen for molecules that may
have a therapeutic effect on SARS-CoV-2.
Develop specific drugs based on the
genomic information and pathological
characteristics of SARS-CoV-2.
1 2 3
SARS-CoV-2 Treatment Strategies

7. 3-1. Target to the Host
• Enhance immune response - such as the
release of interferon.
• Block the signal pathways
required for virus replication.
• Target viral and cell surface receptor
proteins (ACE2).
Object of Specific Drugs

8. • Prevent viral RNA synthesis - target
to the genetic material of the virus.
• Inhibit virus replication - target to
key enzymes of the virus.
• Block the virus’s binding to human
cell receptors or inhibiting the
virus’self-assembly process - target
to the structural proteins of the virus.
Object of Specific Drugs
3-2. Target to SARS-CoV-2

9. Monoclonal antibody/convalescent plasma for ACE2:
Prevent the virus into the host cell.1
science.sciencemag.org/content/367/6485/1412
Camostat mesylate: Prevent SARS-CoV-2 into the cell
by acting on TMPRSS2.2
Lopinavir-Ritonavir: Inhibition of protease activity of
SARS-CoV-2.3
Ribavirin- May inhibit mRNA capping.4
RNA Synthesis Inhibitors: Inhibits SARS-CoV-2 RNA
synthesis and replication.
5
Neuraminidase Inhibitors (NAIs)-Interfere with the
release of progeny influenza virus from infected
host cells.
66
SARS-CoV-2 Treatment Strategies
NAIs
RNA Synthesis
Inhibitors
①
②
③
④
⑤
⑥

10. SARS-CoV-2 Preclinical Research
Drug Discovery Services
In Vitro Diagnostic (IVD) Development
• Anti-SARS-CoV-2 Drug Discovery
• Antibody & Immunoassay Development Services
Creative Biolabs’ SARS-CoV-2 Services
• SARS-CoV-2 Vaccine Discovery
• SARS-CoV-2 Preclinical Research
• Molecular Diagnostic Assay Development Services
• SARS-CoV-2 Related Detection Kits

11. Antibody
Recombinant Proteins
Plasmids
PCR Primers & Probes
Detection Kits
SARS-CoV-2
Antibody
Recombinant Proteins
Plasmids
Protein Expression Products
MERS-CoV
Antibody
Recombinant Proteins
Plasmids
Protein Expression Products
SARS-CoV
Antibody
Recombinant Proteins
Plasmids
Protein Expression Products
Other Coronavirus
RNA Extraction Kits
RNA Extraction Kit
Antibody
Recombinant Proteins
Plasmids
Protein Expression Products
Key Receptor ACE2
Creative Biolabs’ SARS-CoV-2 Products

12. Address: 45-1 Ramsey Road, Shirley, NY 11967, USA
Email: info@creative-biolabs.com
Web: www.creative-biolabs.com
Contact Us